Exsanguination is an underestimated cause of treatment failures in patients with severe trauma or undergoing surgery. In some patients the primary dysfunction of blood clot formation is a direct cause of a massive blood loss. Patients without previous coagulation disorders are at risk of coagulopathy following intraoperative or post-traumatic bleeding, where the local haemostasis does not warrant bleeding cessation. the aim of the study was to assess the therapeutic value of various components of a complex interdisciplinary approach, based on the opinion of the experts treating patients with massive bleeding. Material and methods. The study was conducted by anonymous questionnaire, using the analogue representation of the argument strength. The results were analyzed based on the techniques of descriptive statistics. The argument was considered a key parameter, when the median value of strength was located in the highest quartile. Results. It was found that the arguments of the highest strength for the risk of developing the posthaemorrhagic coagulation disorders are: loss of more than one third of blood volume, fluid therapy in an amount greater than 35 ml / kg, administration of more than 5 units of packed red blood cells, insufficient supply of fresh frozen plasma and platelets in proportion to packed red blood cells, severe acidosis and hypothermia. The most important tests for post-haemorrhage coagulopathy are: anatomically non-localized bleed, abnormal values of the standard coagulation parameters and fibrinogen level below 1 g / L. In the treatment of post-haemorrhagic coagulopathy the team of experts pointed out the benefits of antifibrinolytic drugs, concentrates of prothrombin complex and recombinant activated coagulation factor VII. conclusions. Multidisciplinary therapeutic management of bleeding patients is associated with employment of appropriate treatment methods to achieve the best possible outcome. Factors influencing the development of coagulopathy, the methods of diagnosis and proposed techniques of treatment may facilitate therapeutic decisions in bleeding patients requiring massive transfusion of blood components. tic guidelines (3) . The conduction of controlled clinical studies encounters objective methodological difficulties connected with the patients selection and determination of the degree of homogeneity of the examined groups (4, 5) . Therefore, recommendations are usually elaborated on the basis of conclusions obtained during specialist conferences and opinions of experts and physicians with significant experience (6) .
The aim of this study was to assess the therapeutic value of various components of a complex interdisciplinary approach based on the opinion of experts treating patients with massive bleeding. The use of non-standard techniques is based on the opinion of selected Massive and sudden blood loss is a lifethreatening condition and, regardless of the cause, requires immediate intervention. The therapeutic aim consists in stopping the bleeding and assuring proper tissue perfusion and oxygenation, saving patient's life (1) . Therapeutic decisions in case of bleeding are connected with numerous obstacles, resulting from clinical experience, limited availability of proper medical equipment, blood components, modern infusion fluids, and insufficient skills of therapeutic teams (2) .
Conclusions obtained from research on treatment of patients with massive blood loss, require constant updating of knowledge, and modification of the already existing therapeu-experts and conference conclusions, covering issues of hemostasis disorders during the posttraumatic and perioperative period, considering patients without congenital blood clotting disturbances.
Data concerning issues describing the risk of coagulopathy development, diagnosis, and treatment were collected on the basis of a questionnaire consisting of 28 detailed questions and commentary. Each issue was determined on the basis of an analogue scale (0.0-1.0) used to indicate the weight of the evaluated argument while undertaking the therapeutic decision. The issues presented for experts' evaluation comprised clinical data which might prove helpful in the determination of bleeding-related blood clotting failure. Additionally, the authors presented therapeutic decisions possibly responsible for the development of post-hemorrhage coagulopathy.
Initially, 96 experts were selected on the basis of data obtained from the Association for Severe Bleeding Care with headquarters in Warsaw. Inclusion criteria was authorship in at least one publication covering the nonstandard issue of treating patients with severe bleeding, which was published in a journal from Philadelphia list. Additional qualification criteria included significant clinical experience in the management of patients with massive bleeding and active participation in conferences concerning massive hemorrhage.
The depersonalized questionnaire results were placed in the database and subject to statistical analysis by means of the descriptive statistics technique. The "strength of the argument" median was described as the weight of the parameter subject to expert evaluation and expressed as a percentage. The terminology concerning the amount of transfused packed platelets was based on the so-called therapeutic unit. The therapeutic unit corresponds to 5 units of the concentrate obtained by means of the manual technique (decanted concentrate) or 1 unit of the concentrate obtained by means of the apheresis technique. One therapeutic unit contains an average of 3x10 11 
platelets.
Questionnaire results were obtained from 27 (28%) experts. All obtained questionnaires were complete which enabled result analysis. Considering the expert group the following specialties were represented: eight general surgeons, two cardiac surgeons, nine intensive therapy and anesthesiology experts, three hematologists, three obstetrics and gynecology experts and two hepatologists.
A. Factors favoring the development of posthemorrhagic coagulopathy ( fig. 1) A1. Blood loss during hemorrhage exceeding half of the blood volume (more than 35 ml/kg body weight in patients with a normal BMI, and >30 ml/kg body weight in patients with a BMI>30 kg/m 2 ) is an important factor favoring the development of posthemorrhagic coagulopathy. The argument of strength parameter was assessed at 90%.
Short-lasting blood loss (during a period of 60 minutes) exceeding 20% of the blood volume (12-15 ml/kg body weight), depending on the BMI may contribute to the development of coagulopathy accompanying blood loss. The argument of strength parameter was assessed at 60%.
conclusion. There is an absolute necessity to estimate the volume of exsanguinated blood during hemorrhage. The inconveniences and errors connected with the underestimation of blood loss might have influence on therapeutic decisions. In case of blood loss estimation (during surgery) the above-mentioned data should be included in the management protocol of a bleeding patient.
A2. Fluid therapy in case of bleeding patients is important, considering the risk of possible clinically significant coagulopathy. The argument of strength parameter determining the type of infused fluids was assessed at 90%. Based on the opinion of experts significant coagulopathy risk may be observed when administering fluids corresponding to half of the amount of total circulating blood volume (TCBV). The risk of coagulopathy disorders is increased in case of patients receiving unbalanced fluids.
conclusion. The supplementation of the vascular bed by means of fluids should take into account the composition of the plasma, osmolality, buffer system, and presence of calcium ions in the infusion fluids. In the absence of immediate availability of blood elements, colloid solutions are recommended. The use of the abovementioned is justified, when prior to blood transfusions patients receive fluids corresponding to at least half of the TCBV.
A3. Blood components used in the treatment of massive bleeding have significant influence on the risk of developing secondary coagulopathy. The volume of transfused packed red blood cells is an important factor. The argument of strength parameter was assessed at 100%. Experts consider that coagulopathy may develop when patient received at least 5 units of PRBC. The risk of coagulopathy increases in patients who received at least 5 units of PRBC, less than 1 unit of fresh frozen plasma (FFP), < than 1 unit of platelets, and cryoprecipitate. The argument of strength parameter was assessed at 80%.
conclusion. Primary treatment of hemorrhage by means of PRBC poses the risk of coagulopathy development, in case of transfusion of more than 5 units, especially in the absence of synchronic administration of FFP and platelets. The transfusion of more than 5 units of PRBC should be connected with the transfusion of FFP at a rate of 1 unit per 2 units of PRBC. Bleeding patients should receive platelets at a rate of 1 therapeutic unit per 5 units of PRBC. Similar proportions are suggested when one unit of cryoprecypitate should be administered per two units of PRBC. A4. The transfusion of non-coagulating fluids in actively bleeding patients might be responsible for the development of the so-called "dilution component" leading in consequence to coagulopathy. The argument of strength parameter was assessed at 60% with risk of coagulopathy development, considering patients subject to transfusion of less than 50% of the blood volume.
conclusion. It is recommended that blood elements used in the treatment of severe bleeding should not constitute less than 50% of the overall fluid demand administered to patients during therapy of massive hemorrhage.
A5. Core body temperature < 35°C is an important factor favoring coagulopathy development in actively bleeding patients. The argu-ment of strength parameter was assessed at 80% (median).
conclusion. It is necessary to monitor the core body temperature in bleeding patients. In order to increase the effectiveness of therapy and prevent coagulopathy it is recommended to maintain the core body temperature above 35°C.
A6. The arterial pH below 7.2 and arterial base excess <-10 mEq/L are important factors favoring the development of bleeding-related coagulopathy which influences the efficacy of therapy. The argument of strength parameter of arterial pH was assessed at 90%, while that of the arterial base excess <-10 mEq/L at 80%.
conclusion. During therapy of massive hemorrhage it is necessary to maintain the blood pH level above 7.2 and the arterial base excess below -10 mEq/L, in order to improve therapeutic efficiency. A7. The venous lactate level >5 mmol/L is an important indicator of peripheral tissue ischemia. The argument of strength of the parameter was assessed at 50%. However, the estimated value was rather of prognostic significance when determining the efficacy of treating hemorrhagic shock. The diminishing lactate level during treatment of bleeding may be evidence of the effectiveness of therapy, and return of tissue perfusion, reducing the risk of coagulopathy development.
conclusion. Evaluation of the venous lactate level during treatment of severe bleeding is useful for evaluation the efficacy of therapy. Serial lactate level determination in actively bleeding patients is of limited value, and is not recommended.
B. Diagnosis of posthemorrhagic coagulopathy ( fig. 2) B1. The observation of the operative field and/or imaging examination results is the key element in the diagnosis of posthemorrhagic coagulopathy. The surgical or intravascular management of bleeding, anatomically located, is the key method of stopping massive blood loss. The most important factor is the presence of non-localized bleeding, so called oozing or micro-vessel hemorrhage. The argument of strength of the parameter was assessed at 90%.
conclusion. The determination of nonlocalized anatomical bleeding may indicate the presence of clotting disorders accompanying active bleeding, requiring the implementation of systemic prohemostatic therapy. B2. Laboratory results determining the efficacy of the coagulation system are an important indicator of posthemorrhagic coagulopathy diagnosis, enabling additionally diagnose in some patients with previously unrecognized coagulation disorders. The standard coagulogram (prothrombin time, fibrinogen and Ddimers levels, partial thromboplastin time after activation) is of significant value in case of actively bleeding patients. The argument of strength parameter was assessed at 100%. The fibrinogen concentration <1 g/L is an important factor indicating the high risk of coagulopathy resistance to prohemostatic drugs.
conclusion. It is necessary to perform a standard coagulogram in patients with active bleeding, which allows preliminary assessment of coagulation factors deficiency and target coagulopathy therapy.
B3. Non-standard coagulation tests show significant usefulness in the differentiation of coagulopathy reasons. However, the argument of strength parameter was assessed at 50%, due to the lack of standardization, and limited availability of specialist laboratory tests. Promising thromboelastometric results may soon verify the current recommendation, and the increased availability of equipment will facilitate the therapeutic decision.
conclusion. Thromboelastometric measurements and the evaluation of the activity of blood clotting factors brings important information concerning the function of hemostasis in patients with clotting disorders accompanying massive bleeding. The availability of the measuring equipment to perform customized coagulation tests currently limits the use of these techniques in everyday clinical practice, in Poland.
C. Management of coagulopathy accompanying massive blood loss ( fig. 3) C1. Antifibrinolytic drugs. The use of antifibrinolytic drugs is an important element in the management of coagulopathy, accompanying massive blood loss. The argument of strength was assessed at 80%.
conclusion. Antifibrinolytic treatment is the recommended method in active bleeding patients.
C2. Desmopressin. The use of desmopressin in patients with massive hemorrhage is of limited use. The argument of strength param- eter was assessed at 40%. The role of desmopressin in patients' with von Willebrand's disease (type 1 and 2), thrombocytopathy, mild hemophilia type A, or subject to previous treatment by means of anticoagulants of unknown antidote, was underlined. Secondary thrombocytopathies during the course of chronic renal failure, for example may be a reasonable indication for desmopressin therapy (argument of strength assessed at 80%). conclusion. Treatment with desmopressin is of secondary importance in case of active bleeding, with the exception of patients with a documented or suspected platelet dysfunction, a mild form of type A hemophilia, and von Willebrand's disease (type 1 and 2).
C3. Protamine sulphate. Therapy using protamine sulphate in bleeding patients is of fundamental importance in case of therapy with non-fractionated heparin. The administration of protamine sulphate in patients that did not receive unfractionated heparin has no prohemostatic significance (the argument of strength parameter was assessed at 30%).
conclusion. In case of patients receiving unfractionated heparin the use of protamine sulphate is clinically effective and highly recommended.
C4. Catecholamines during active bleeding have no prohemostatic significance and should not be regarded as a factor responsible for the effective treatment of patients with massive blood loss (argument of strength parameter assessed at 10%). The use of catecholamines in order to obtain hemodynamic stabilization and assure proper celiac flow should be individually considered, depending on the clinical situation, and not dealt with in terms of hemostasis.
conclusion. The use of catecholamines during therapy of massive blood loss has no effect on bleeding cessation, and should only be evaluated in terms of hemodynamic control, and to ensure proper tissue perfusion in active bleeding patients.
C5. Prothrombin coagulation factor concentrates (factors II, VII, IX and X). The use of prothrombin coagulation factor concentrates is important in patients with active bleeding and symptoms of liver insufficiency, or previously treated by means of vitamin K antagonists (argument of strength assessed at 100%). Severe hemodilution as a consequence of massive blood loss may require the administration of prothrombin factors (argument of strength assessed at 60%).
conclusion. The usefulness of prothrombin coagulation factor concentrates in the management of patients with active bleeding, and symptoms of prothrombin complex factor insufficiency may be pathophysiologically justified. The above-mentioned may be used as a substitute of freshly frozen plasma in patients requiring volume reduction of infused fluids and blood products.
C6. Recombinant, activated coagulation factor VII (rFVIIa). The usefulness of factor rFVIIa is significant in patients with active bleeding and coexisting coagulopathy, dependent on massive blood loss and extensive tissue damage. The argument of strength was assessed at 90%.
conclusion. The use of the recombinant activated factor VII is indicated in patients with massive bleeding and coexisting coagulopathy, who do not respond to substitutive therapy. Platelet dysfunction, vascular diathesis, and anticoagulation drug therapy in patients with massive bleeding may be an additional indication for the use of the recombinant activated factor VIIa. The greatest therapeutic efficacy can be achieved when controlling the acid-base balance (pH>7.2), hypothermia (core body temperature >35 0 C), and rational treatment of bleeding, maintaining the fibrinogen level above 1 g/L and platelet count above 50 G/L. In selected cases, considering patients with active and massive bleeding, rFVIIa use is permitted without previous coagulation diagnostics in order to save the life of the patient delaying therapeutic decisions and obtain relevant laboratory test results.
DISCUSSION
Clotting disorders during the postoperative or posttraumatic period may be responsible for uncontrolled bleeding, influencing treatment results (7) . Based on the opinion of Polish experts there exist many factors increasing the risk of coagulopathy development during the postoperative and posttraumatic period. Rational management of bleeding patients may decrease the risk of post-hemorrhagic clotting disturbances leading towards the reduction of transfusions improving treatment results (4).
Based on the numerous opinions it can be assumed that the high risk of coagulopathy concerns patients with the loss of half of total circulating blood volume (TCBV) Loss of 20% of the blood volume, hemodynamically significant, due to the short-lasting bleeding, is insufficient for the development of coagulopathy. Thus, criteria for massive blood loss are not necessarily connected with risk of coagulopathy development (8) . The recommendations established by the group of experts demonstrate the significance of the mechanism of dilution of blood components in case of hemostasis disturbances, which may develop in case of one third of TCBV (9) .
The type of fluid therapy is connected with the volume of blood loss (9) . The type of infusion fluids may be a key element in the development of coagulopathy accompanying bleeding. When providing the fluid intake in patients with more than 30% of blood loss it is necessary to consider the electrolyte balance, osmolality, and type of buffer. Based on clinical and experimental data the lowest risk of clotting disturbances during fluid therapy (due to bleeding), concerns patients receiving colloid solutions supplemented by calcium ions (9, 10, 11). Low-volume fluid therapy and hypertonic solutions are used in the early phase of resuscitation in patients with massive bleeding, as well as in case of patients with controlled bleeding (12) . The transfusion of more than 5 units of packed red blood cells in case of massive blood loss is indirect evidence of the amount of blood loss, often exceeding 50% of the blood volume (13, 14) . Polish experts demonstrated that the transfusion of more than 5 units of packed red blood cells is connected with increased risk of coagulopathy. Additionally, packed red blood cells should be transfused with fresh frozen plasma, platelets and fibrinogen. The supplementation of lost blood by means of synchronous administration of the above-mentioned enables to limit the dilution effect responsible for coagulopathy (6) . Benefits connected with the implementation of massive blood transfusion protocols in actively bleeding patients were documented in numerous analyses (15) . Currently, the simultaneous administration of different blood elements at a ratio of 1:1:1 (packed red blood cells: freshly frozen plasma: platelet concentrate) limits the dilution effect, prevents coagulopathy and reduces mortality in patients after trauma (16) .
In case of patients with massive blood loss the transfusion of blood components should be initiated as soon as possible, in order to limit the dilution effect (17) . Another therapeutic method may be implemented in case of patients with controlled bleeding, where fluid resuscitation consists in the management of anemia (13, 18) . The management of posthemorrhagic anemia depends on the patients' general condition and packed red blood cell protocol. Venous hemoglobin saturation below 70% might be a helpful indicator, considering the need to transfuse packed red blood cells. In case of patients with non-controlled bleeding one should strive towards the limitation of non-coagulation fluids, in order to limit the dilution anticoagulation effect (1) .
The hypothermia and acidosis control is of great importance in preventing the coagulopathy associated with massive blood loss. The share of hypothermia and acidosis in hemostasis development disturbances has been repeatedly emphasized. The maintenance of the core body temperature above 35 0 C and arterial pH > 7.2 corresponds to the generally accepted criteria of complex resuscitation in bleeding patients (3) . The warming of a bleeding patient and raising their pH, in order to maintain the arterial base excess below -10 mEq/L should be conducted from the beginning of resuscitation (7). The value of the venous lactate level, based on the experts' opinions is not of decisive importance considering the occurrence of coagulopathy, being an indicator of tissue hypoperfusion (19). Restoration of proper tissue perfusion is the key goal in the shock-related acidosis. The correction of the arterial base excess by sodium bicarbonate infusions does not prevent coagulopathy and should be reserved for specific clinical situations. The experts opinions are consistent with literature data, where the lactate concentration does have significant prognostic value, considering patients in shock, but does not imply the therapeutic decision (20).
The diagnosis of coagulation failure complicating massive bleeding is a significant clinical problem, which has not yet been resolved. Various criteria indicative of acquired coagulation disorders have been assumed, but their clinical use is uncommon. The obtained study result indicates that the clinical examination confirming the unlocalized bleeding enables diagnosis of posthemorrhagic coagulopathy.
Microvessel bleeding was emphasized by other authors, and therefore its diagnostic value has proper weight (21, 22 ). Considering the above-mentioned analysis, the experts demonstrated the necessity to perform standard coagulogram and platelet count measurements in patients with massive blood loss. The obtained results may confirm the symptoms of a complex coagulopathy. Currently, it is assumed that a 1.5 fold increase in prothrombin time (PT) or partial thromboplastic time (aPTT), in comparison to normal values may be a useful indicator confirming clinically observed symptoms of coagulopathy. According to the opinion of Polish experts the platelet count < 100 G/L or fibrinogen concentration below 1 g/L are indicative of complex posthemorrhagic coagulopathy.
The need for fibrinogen deficiency supplementation in actively bleeding patients is commonly emphasized. It is assumed that fibrinogen level reduction below 1.5 g/L, requires the administration of cryoprecipitate or fibrinogen (3, 6, 11) .
Posthemorrhagic thrombocytopenia and low fibrinogen levels indicates the involvement of the dilution mechanism especially in patients treated by means of infusion fluids without supplementation of blood components. The significance of platelets and fibrinogen in primary and secondary hemostasis requires proper supplementation in patients with massive blood loss, so as to obtain conditions for the production of stable clots at the site of the damaged vessels (21, 23) .
The role of thromboelastometry in patients with massive blood loss is of limited value in Polish conditions due to difficulties in accessing appropriate measuring equipment. Experts from referential centers performing thromboelastometry indicate high usefulness of obtained results, especially considering primary fibrinolysis and clot formation. It is assumed that the evolution of the response to injury is dependent on the function of the vascular epithelium, and the activation of the fibrinolytic system may be diagnosed during thromboelastometry, enabling to implement proper therapy of coagulopathy (24) . The accessibility of tromboelastometry permits rational treatment of patients with coagulopathy-related bleeding (25) .
Platelet function measurements consisting in the estimation of the occlusion time (PFA-100, Siemens, Germany) or adhesion and aggregation by means of the Impact-R test is of significant value in bleeding patients receiving antiplatelet drugs. Thus, the usefulness of platelet function evaluation is indicated by experts in the field of cardiosurgery and cardioanesthesia (26) .
The activation of the vascular endothelium, connected with the reduction of the activity of fibrinolysis factor inhibitors (PAI-1) increases the plasma fibrinolytic activity in patients after trauma, reducing the possibility of clot formation (8) . For this reason, many authors recognized the intention of early anti-fibrinolytic treatment in case of patients who suffered extensive injuries, and are at risk of hemorrhage. Benefits connected with early anti-fibrinolytic treatment were proven in the CRASH-2 trial (27) . The choice of the anti-fibrinolytic drug is important. Currently, one can assume that tranexamic acid will remain the drug of choice (initial dose-2 g during 10 minutes, and half of the dose after 8 hours or 1 g every 8 hours), and initiation of treatment should precede the surgical intervention (27, 28) .
Interest in desmopressin in patients with active bleeding results from the ability to stimulate platelet aggregation and adhesion, especially in case of primary and secondary platelet dysfunction. Considering patients with von Willebrand's disease (type 1 or 2) the administration of desmopressin increases the activity of von Willebrand's factor (29) . In patients without platelet dysfunction, where coagulopathy is a consequence of massive blood loss have little chance to benefit from desmopressin therapy (30). The limitation of desmopressin administration in patients with active bleeding consists in its vasoconstrictive activity, and release of von Willebrand multimers. In case of patients with anemia or those hemodynamically unstable, the above-mentioned may lead towards overt symptoms of ischemia, such as acute coronary syndrome (31) . Thus, Polish experts cautiously evaluated the use of desmopressin in patients with active bleeding.
The use of protamine sulphate is currently regarded as an antidote in patients treated by means of unfractionated heparin. Hemorrhage dependent on the administration of heparin is characterized by the presence of non-localized bleeding, depending on the extent of sustained injury. The reversal of the activity of heparin by protamine sulphate might restore the possibility of clot formation in the absence of other factors responsible for coagulopathy development, such as increased protein C activity, and platelet or plasma disorders. It may be assumed that in patients receiving heparin, diagnosis of bleeding should imply the reversal of the effect of heparin, as to determine the anatomical cause of bleeding or hemostasis defect (32) .
The use of catecholamines in patients with active bleeding is of secondary importance. Despite the possible activation of the platelet function under the influence of adrenalin one may expect the reduction of tissue flow and increased anaerobic metabolism, considering peripheral tissues which in consequence leads towards clot formation disturbances (33) .
The transfusion of lost coagulation factors in patients with active bleeding has a rational theoretical basis. Given the fact that some plasma proteins demonstrate acute phase protein activity, one should not expect the synchronous decrease in the activity of all coagulation factors, and the concept of dilution coagulopathy does not explain the observed abnormalities during active bleeding. Currently, it can be assumed that patients with coagulation factor deficiencies dependent of vitamin K will benefit most from treatment with prothrombin complex coagulation factor concentrates (34) . An important indication for the consideration of treatment by means of blood clotting factor concentrates is the significant hemodilution or need to reduce the amount of transfused fluids in selected clinical situations connected with heart or kidney insufficiency (35) .
The transfusion of rFVIIa has its pathophysiological justification in actively bleeding patients with congenital hemophilia complicated by inhibitor, acquired hemophilia, congenital VII factor deficiency, and in patients with rare platelet dysfunctions, such as Glanzmann's trombasthenia (36) . The mechanism of action of high doses of rFVIIa consists in the generation of high doses of thrombin at the site of exposure to the tissue factor and platelet surface, which enables fibrin clot formation resistant to fibrinolysis (37). Thus, rFVIIa has been often used as a prohemostatic drug in patients with massive bleeding, with or without previously observed or haemostasis disorders (38) . Currently, the number of applications for the use of rFVIIa is estimated in the thousands and the often presented encouraging therapeutic effectiveness is an argument for further investigations (39).
CONCLUSIONS
On the basis of the performed analysis the weight of the predicting factors and clinical indicators was determined, enabling to diagnose posthemorrhagic coagulation disorders, which may be an indication for the initiation of systemic treatment. The selection of fluid therapy, maintaining the proportion of different blood components in case of managing patients with active bleeding and the acid-base balance, core body temperature may facilitate treatment and improve its effectiveness. The consideration of systemic therapy, based on antifibrinolytic drugs, and active and inactive coagulation factors enable to reduce the volume of transfused fluids, enabling to maintain a stable thrombus in patients with congenital and acquired coagulopathy, in the event of sudden blood loss. We hope that further research will provide the basis for the designation of clear clinical guidelines. Currently, insufficient study results that provide scientific evidence do not give grounds for the formulation of thesis disqualifying or promoting a particular treatment regimen. Based on the study report the choice of the fluid therapy model, and sequence of antifibrinolytic and prohemostatic drugs used is not without significance, and should be based on the knowledge of pathophysiological disturbances accompanying massive blood loss.
